Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Leukemia

 

CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01696084

Combination Chemotherapy for Young Patients With Newly Diagnosed T-Cell ALL (COG AALL0434)
Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia

Investigator: Blythe Thomson, MD;   Conditions: Acute Lymphoid Leukemia (ALL);    Status: Recruiting;   Study ID: NCT00408005

Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Investigator: John Pagel, MD, PhD;   Conditions: Leukemia, Lymphoma;    Status: Recruiting;   Study ID: NCT00918723

IAP for Induction of Newly Diagnosed Acute Myeloid Leukemia (2674)
Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)

Investigator: Raya Mawad;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01831232

Tosedostat with Cytarabine or Decitabine for AML
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01567059

Marqibo® for Older Patients w/ Newly Diagnosed ALL (20112071)
A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects = 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Investigator: Andrei Shustov, MD;   Conditions: Acute Lymphoid Leukemia;    Status: Recruiting;   Study ID: NCT01439347

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients (2572)
A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01756677

GA101 (RO5072759) for Previously Untreated Chronic Lymphocytic Leukemia (2514)
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Investigator: Ajay K. Gopal, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01300247

Combination Chemotherapy for Young Patients with ALL (COG AALL0331)
COG - Standard Risk B-Precursor Acute Lymphoblastic Leukemia: A Phase III Group Wide Study

Investigator: Blythe Thomson, MD;   Conditions: Acute Lymphoid Leukemia (ALL);    Status: Closed;   Study ID: NCT00103285

Outpatient Induction Chemotherapy for Newly Diagnosed AML or MDS (7910)
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Investigator: Pamela S. Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01807091

Liposomal Cytarabine-Daunorubicin CPX-351 for Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (2642)
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Investigator: Roland B. Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01804101

Oral Azacitidine for MDS, CMML and AML (2474)
A Phase I, Open-Label, Dose-Escalation Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).

Investigator: Bart Scott, MD;   Conditions: Myelodysplastic Syndromes (MDS);, Chronic Myelomonocytic Leukemia (CMML);, Acute Myelogenous Leukemia (AML);    Status: Closed;   Study ID: NCT00528983

PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies

Investigator: Vivian Oehler, M.D,;   Conditions: Hematologic Malignancies;    Status: Closed;   Study ID: NCT00953758

Bendamustine Hydrochloride and Idarubicin for Previously Untreated AML or MDS (2413)
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Closed;   Study ID: NCT01141725

Idelalisib + Bendamustine and Rituximab for Untreated CLL (9064)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01980888